
|Articles|December 22, 2011
Dr. Susan Urba Discusses Cost Concerns for Treatment of Chemotherapy-Induced Nausea
Advertisement
In this segment, Dr. Susan Urba, University of Michigan, Comprehensive Cancer Center, talks about treatment guidelines and decisions relevant to chemotherapy-induced nausea and vomiting (CINV) in a managed care setting.
In addition, Dr. Urba warns of the consequences associated with the treatment of CINV when cost concerns impact best practices. Often, these consequences can include increased costs from uncontrolled symptoms and potential hospital admission due to dehydration.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
TrumpRx Launch Brings Savings—and Uncertainty
2
As Cencora Closes With OneOncology, Patton Says Terms Show “Trust”
3
Benefits, Tradeoffs of Medically Integrated Dispensing in Oncology Care: Katherine Tobon, PharmD, BCOP
4
Asundexian Reduces Risk of Stroke Recurrence in Phase 3 OCEANIC-STROKE Trial
5








